A phase I study of ALX-1141 in healthy volunteers

Trial Profile

A phase I study of ALX-1141 in healthy volunteers

Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs ALX-1141 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Aug 2017 New trial record
    • 24 Aug 2017 According to an Ablynx media release, the company is planning to initiate the single ascending dose part of the study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top